Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Stewart et al. (Sat,) studied this question.

synapsesocial.com/papers/69d842d2d56ca42147d17e87 https://doi.org/https://doi.org/10.1056/nejmoa1411321

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma2013 · 128 citations
2A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma2014 · 183 citations
3Discrete sequential boundaries for clinical trials1983 · 1,740 citations
4Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.2014 · 7 citations
5Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.2013 · 16 citations

Bookmark

View Full Paper